BiiG THERAPEUTICS LIMITED – Trademark Portfolio
Entity Type: 16
BiiG THERAPEUTICS LIMITED holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BRII BIOSCIENCES BREAKTHROUGH INNOVATION & INSIGHT. The owner is based in SHANGHAI.
#33, LANE 1000, ZHANGHENG RD PUDONG DIST
SHANGHAI 201203 , CN
Showing of trademarks Trademarks
Trademark Classifications
BiiG THERAPEUTICS LIMITED's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BiiG THERAPEUTICS LIMITED have?
BiiG THERAPEUTICS LIMITED has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned.
What trademark classes does BiiG THERAPEUTICS LIMITED file in?
BiiG THERAPEUTICS LIMITED files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 42 covers scientific and technological services; industrial analysis and research services.
What are BiiG THERAPEUTICS LIMITED's most well-known trademarks?
BiiG THERAPEUTICS LIMITED's registered trademark portfolio includes well-known marks such as BRII BIOSCIENCES BREAKTHROUGH INNOVATION & INSIGHT. These are among 1 currently registered trademark in the portfolio.
What is BiiG THERAPEUTICS LIMITED's trademark registration success rate?
BiiG THERAPEUTICS LIMITED has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.